Biogen Inc (NASDAQ:BIIB) – Stock analysts at Leerink Swann cut their FY2022 EPS estimates for shares of Biogen in a research note issued to investors on Monday, October 15th. Leerink Swann analyst G. Porges now forecasts that the biotechnology company will post earnings per share of $24.86 for the year, down from their prior forecast of $25.11.

A number of other equities analysts have also recently issued reports on BIIB. BidaskClub cut Biogen from a “buy” rating to a “hold” rating in a report on Tuesday, June 19th. Mizuho set a $423.00 target price on Biogen and gave the stock a “buy” rating in a report on Friday, June 29th. Citigroup upgraded Biogen from a “neutral” rating to a “buy” rating and set a $371.00 target price for the company in a report on Friday, July 6th. Canaccord Genuity set a $335.00 target price on Biogen and gave the stock a “buy” rating in a report on Friday, July 6th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Biogen in a report on Friday, July 6th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and twenty-three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $381.31.

BIIB stock opened at $328.41 on Tuesday. The stock has a market cap of $71.17 billion, a price-to-earnings ratio of 15.06, a PEG ratio of 1.36 and a beta of 0.86. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.36 and a quick ratio of 2.06. Biogen has a 1 year low of $249.17 and a 1 year high of $388.67.

Biogen (NASDAQ:BIIB) last released its earnings results on Tuesday, July 24th. The biotechnology company reported $5.80 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $5.22 by $0.58. The firm had revenue of $3.36 billion during the quarter, compared to analysts’ expectations of $3.25 billion. Biogen had a return on equity of 38.17% and a net margin of 23.06%. The company’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.04 EPS.

A number of large investors have recently modified their holdings of the stock. Rainier Group Investment Advisory LLC acquired a new stake in Biogen during the first quarter worth approximately $100,000. NEXT Financial Group Inc acquired a new stake in Biogen during the third quarter worth approximately $133,000. Point72 Asia Hong Kong Ltd acquired a new stake in Biogen during the first quarter worth approximately $105,000. Adviser Investments LLC lifted its position in Biogen by 745.7% during the second quarter. Adviser Investments LLC now owns 389 shares of the biotechnology company’s stock worth $113,000 after acquiring an additional 343 shares during the last quarter. Finally, McKinley Carter Wealth Services Inc. acquired a new stake in Biogen during the first quarter worth approximately $110,000. Institutional investors and hedge funds own 87.46% of the company’s stock.

In other news, EVP Michael D. Ehlers sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, September 26th. The stock was sold at an average price of $350.00, for a total value of $350,000.00. Following the completion of the transaction, the executive vice president now owns 4,281 shares in the company, valued at approximately $1,498,350. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.29% of the stock is owned by company insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.

Read More: NASDAQ Stock Market Explained

Earnings History and Estimates for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.